
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing phenoxybenzamine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing phenoxybenzamine are listed in capsule form. No finished phenoxybenzamine product of any kind is listed in liquid form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Phenoxybenzamine hydrochloride is a long-acting alpha-adrenergic blocker taken by mouth that pharmacies may compound, including as an oral suspension, on prescription.
Phenoxybenzamine hydrochloride is a long-acting alpha-adrenergic receptor blocker. It binds permanently to alpha receptors on blood vessels and other tissues, blocking signals from adrenaline-like hormones; this widens blood vessels, increases blood flow to the skin and abdominal organs, and lowers blood pressure lying and standing. Manufactured products are phenoxybenzamine hydrochloride capsules sold under ANDAs, such as Aurobindo's; the original brand, Dibenzyline (NDA), is listed by FDA as discontinued. The capsules are labeled for pheochromocytoma, a hormone-releasing adrenal tumor, to control episodes of high blood pressure and sweating. A prescriber might order phenoxybenzamine compounded as an oral liquid, for which a USP compounded oral suspension monograph exists, or in a strength that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Phenoxybenzamine labels carry no boxed warning. Do not use it if a drop in blood pressure would be harmful or if you are allergic to it or its ingredients. Expected effects of alpha blockade include dizziness or fainting on standing, fast heartbeat, stuffy nose, small pupils and trouble ejaculating; stomach upset, drowsiness and tiredness can also occur. Medicines that stimulate both alpha and beta receptors, such as epinephrine, can cause an exaggerated blood pressure drop and fast heartbeat. Cancer has been reported in people after long-term use, so long-term use is not recommended. Tell your prescriber about heart, brain blood vessel or kidney disease, or a respiratory infection. The label says to use it in pregnancy only if clearly needed and to choose between nursing and the drug. Call your prescriber right away for fainting, fast heartbeat or vomiting, and talk to your prescriber or pharmacist about other side effects.
Phenoxybenzamine is a nonselective, irreversible antagonist of alpha-1 and alpha-2 adrenergic receptors that binds covalently (StatPearls); per the Aurobindo label it produces a "chemical sympathectomy" with no parasympathetic effect. Oral PK (label): 20 to 30% of an oral dose appears to be absorbed in active form; the oral half-life is unknown, while the intravenous half-life is about 24 hours, effects persist at least 3 to 4 days, and daily dosing is cumulative for nearly a week. Labeled indication (phenoxybenzamine hydrochloride capsules, Aurobindo, ANDA): pheochromocytoma, to control episodes of hypertension and sweating; a beta blocker may be needed if tachycardia is excessive. USP publishes a Phenoxybenzamine Hydrochloride Compounded Oral Suspension monograph. StatPearls lists neurogenic bladder, functional outlet obstruction and partial prostatic obstruction among off-label uses, and MedlinePlus also describes these bladder uses; these are not FDA-approved indications. Use caution with marked cerebral or coronary arteriosclerosis or renal damage. Ames and mouse lymphoma assays were positive, rodent studies showed gastrointestinal and peritoneal tumors, and human carcinoma case reports followed long-term use. Dosing is per prescriber. StatPearls advises monitoring seated and standing blood pressure because of possible marked hypotension and tachycardia.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally